uniQure to Participate in Multiple Upcoming Industry Conferences

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 28, 2018 (GLOBE NEWSWIRE) -- (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in October:

• Leerink Partners Roundtable Series: Rare Disease & Oncology at the Lotte New York Palace Hotel, in New York City.
  
   
  • Matt Kapusta will participate in a fireside chat moderated by Leerink analyst Joseph Schwartz, on Tuesday, October 2^nd at 3:00 p.m. ET. The live webcast can be accessed through the link displayed in the . The webcast replay will be available for at least 72 hours following the live event.
    
     
• 2018 Cantor Global Healthcare Conference at the InterContinental New York Barclay Hotel, in New York City.  
  
   
  • , chief executive officer at uniQure, will present a corporate update on Wednesday, October 3^rd at 9:10 a.m. ET. The live webcast can be accessed through the link displayed in the . The webcast replay will be available for at least 72 hours following the live event.
    
     
• Cell & Gene Meeting on the Mesa at the Estancia La Jolla Hotel & Spa, in La Jolla, CA. 
  
   
  • , chief business officer at uniQure, will participate in the spotlight session: “Commercializing Gene Therapies for Hemophilia”, on Wednesday, October 3^rd at 10:45 a.m. PT, and present a corporate update on Wednesday, October 3^rd at 2:45 p.m. PT.
    
     
• Chardan 2^nd Annual Genetic Medicines Conference at the Westin New York Grand Central, in New York City.
  
   
  • , M.D., Ph.D., chief medical officer at uniQure, will participate in a fireside chat moderated by Chardan analyst Gbola Amusa, on Tuesday, October 9^th at 10:00 a.m. ET.
    
     
• 26th Annual Congress of the European Society for Gene and Cell Therapy (ESGCT) at the Swiss Tech Convention Center, in Lausanne, CH.
  
   
  • Multiple abstracts have been accepted for presentation at the scientific conference being held October 16-19, 2018.  Further details to be announced when ESGCT convenes. 
    
     
• 2nd Annual Gene Therapy for Rare Disorders Conference at the Novotel London West, in London, UK.
  
   
  • , M.D., Ph.D., chief scientific officer at uniQure, will participate in a panel discussion: “Gaining Insights into How Investors View the Gene Therapy Space”, on October 23^rd at 2:00 p.m. GMT.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with liver/metabolic, central nervous system and cardiovascular diseases.